AbbVie ducks bolt-on trend and agrees Allergan mega-mergerUS drugmaker AbbVie has agreed to buy struggling Allergan in a $63 billion deal that continues a slew Share XAbbVie ducks bolt-on trend and agrees Allergan mega-mergerhttps://pharmaphorum.com/news/abbvie-ducks-bolt-on-trend-and-agrees-allergan-mega-merger/
BMS will shed Otezla to push Celgene takeover throughBristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion Share XBMS will shed Otezla to push Celgene takeover throughhttps://pharmaphorum.com/news/bms-will-shed-otezla-to-push-celgene-takeover-through/
Vectura seeks new CEO as Ward-Lilley steps downUK-listed Vectura has started the search for a new chief executive, after revealing current CEO James Ward-Lilley will Share XVectura seeks new CEO as Ward-Lilley steps downhttps://pharmaphorum.com/news/vectura-seeks-new-ceo-as-ward-lilley-steps-down/
Huntsworth picks Annabelle Sandeman for global strategy roleAnnabelle Sandeman has been appointed as the new global head of commercial strategy at London-based healthcare and communications Share XHuntsworth picks Annabelle Sandeman for global strategy rolehttps://pharmaphorum.com/news/huntsworth-health-annabelle-sandeman/
UDG Healthcare acquires Putnam Associates and Incisive HealthUDG Healthcare has boosted its Ashfield Communications and Advisory business with a brace of deals, acquiring Putnam Associates Share XUDG Healthcare acquires Putnam Associates and Incisive Healthhttps://pharmaphorum.com/news/udg-healthcare-putnam-incisive-health/
Shingles vaccine boosts GSK as generic Advair bitesGSK’s first quarter sales beat estimates, helped along by shingles vaccine Shingrix and partly offsetting the effect of Share XShingles vaccine boosts GSK as generic Advair biteshttps://pharmaphorum.com/news/shingles-vaccine-boosts-gsk-as-generic-advair-bites/
FDA approves first medical device ADHD treatmentUS regulators have given the green-light for the first medical device to treat attention deficit hyperactivity disorder (ADHD). Share XFDA approves first medical device ADHD treatmenthttps://pharmaphorum.com/news/fda-approves-neurosigma-adhd/
The Bloc promotes Jennifer Matthews to CEO and presidentNew York-based healthcare creative agency The Bloc has promoted managing partner Jennifer Matthews to CEO and president. It’s Share XThe Bloc promotes Jennifer Matthews to CEO and presidenthttps://pharmaphorum.com/news/the-bloc-promotes-jennifer-matthews-ceo/
Boehringer’s blockbuster Spiriva under pressure, profits downBoehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, Share XBoehringer’s blockbuster Spiriva under pressure, profits downhttps://pharmaphorum.com/news/boehringer-ingelheim-2018-sales-profits/
